Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’

Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.

Democratic Presidential Candidate Hillary Clinton’s proposal for lowering US drug costs includes a focus on leveraging privately conducted comparative effectiveness research to enable increased pressure on drug pricing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America